Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man.

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ <i>neu</i> Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · see citing works

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871 · see citing works

CLINICAL CANCER RESEARCH

Smithers, D. W. (1956) · The Lancet · doi:10.1016/s0140-6736(56)91184-9 · Cited by 1,796 · see citing works

erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells

Fiore, P. P. D., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., & Aaronson, S. A. (1987) · Science · doi:10.1126/science.2885917 · Cited by 1,011 · see citing works

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

Wakeling, A. E., Guy, S. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Barker, A. J., & Gibson, K. H. (2002) · PubMed · doi:10.7270/q2pc374f · Cited by 925 · see citing works

The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy

Woodburn, J. R. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00045-x · Cited by 834 · see citing works

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Ranson, M., Hammond, L. A., Ferry, D. K., Kris, M. G., Tullo, A. B., Murray, P. I., Miller, V. A., Averbuch, S. D., Ochs, J., Morris, C. Q., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.112 · Cited by 764 · see citing works

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., & Kris, M. G. (2000) · PubMed · Cited by 761 · see citing works

Drug binding to human alpha-1-acid glycoprotein in health and disease.

Kremer, J. M., Wilting, J., & Janssen, L. H. M. (1988) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00015-8 · Cited by 584 · see citing works

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

Herbst, R. S., Maddox, A., Rothenberg, M. L., Small, E. J., Rubin, E. H., Baselga, J. M., Rojo, F., Hong, W. K., Swaisland, H., Averbuch, S. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.038 · Cited by 572 · see citing works

Role of transport proteins in drug absorption, distribution and excretion

Ayrton, A. D., & Morgan, P. M. (2001) · Xenobiotica · doi:10.1080/00498250110060969 · Cited by 426 · see citing works

Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer.

Sainsbury, J. R. C., Malcolm, A. J., Appleton, D. R., Farndon, J. R., & Harris, A. L. (1985) · Journal of Clinical Pathology · doi:10.1136/jcp.38.11.1225 · Cited by 226 · see citing works

Binding of Drugs to Eye Melanin Is Not Predictive of Ocular Toxicity

Leblanc, B., Jezequel, S. G., Davies, T., Hanton, G. C., & Taradach, C. (1998) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.1998.1243 · Cited by 179 · see citing works

Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).

Heimberger, A. B., Learn, C. A., Archer, G. E., McLendon, R. E., Chewning, T. A., Tuck, F. L., Pracyk, J. B., Friedman, A. H., Friedman, H. S., Bigner, D. D., et al. (2002) · PubMed · Cited by 169 · see citing works

Drug Metabolism and Disposition

Silva, M. F. B., IJlst, L., Allers, P., Jakobs, C., Durán, M., de Almeida, I. T., & Wanders, R. J. A. (2024) · Drug Metabolism and Disposition · doi:10.1124/dmd · Cited by 125 · see citing works

Anti-epidermal growth factor receptor drugs in cancer therapy

Tortora, G., & Ciardiello, F. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.6.755 · Cited by 101 · see citing works

Clinical Pharmacokinetics of the Monoamine Oxidase-A Inhibitor Moclobemide*

Mayersohn, M., & Guentert, T. W. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529050-00002 · Cited by 61 · see citing works

A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain

Villano, J. L., Mauer, A. M., & Vokes, E. E. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg153 · Cited by 51 · see citing works

Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog

McKillop, D., Partridge, E. A., Hutchison, M., Rhead, S., Parry, A. C., Bardsley, J., Woodman, H. M., & Swaisland, H. (2004) · Xenobiotica · doi:10.1080/00498250400009189 · Cited by 46 · see citing works

Tyrosine Kinase Inhibitors

Workman, P., Brunton, V. G., & ROBINS, D. J. (2012) · SpringerReference · doi:10.1007/springerreference_138029 · Cited by 35 · see citing works

Timolol metabolism in man and laboratory anamals.

Tocco, D. J., Duncan, A. E., Deluna, F. A., Smith, J. L., Walker, R. W., & VandenHeuvel, W. J. A. (1980) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)00263-6 · Cited by 23 · see citing works

Studies on the metabolism of 4-fluoroaniline and 4-fluoroacetanilide in rat: formation of 4-acetamidophenol (paracetamol) and its metabolites via defluorination and N-acetylation

Scarfe, G. B. (1999) · Xenobiotica · doi:10.1080/004982599238759 · Cited by 19 · see citing works

Formation of a defluorinated metabolite of a quinoxaline antiviral drug catalysed by human cytochrome P450 1A2

Mutch, P. J., Dear, G. J., & Ismail, I. M. (2001) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357011775479 · Cited by 18 · see citing works

New targets for therapeutic attack

Wakeling, A. E., Barker, A. J., Davies, D. H., Brown, D. S., Green, L. R., Cartlidge, S. A., & Woodburn, J. R. (1997) · Endocrine Related Cancer · doi:10.1677/erc.0.0040351 · Cited by 14 · see citing works

Intratumoral and plasma concentrations of gefitinib in breast cancer patients: Preliminary results from a presurgical investigatory study (BCIRG 103)

McKillop, D., Raab, G., Eidtmann, H., Furnival, A., Riva, A., Forbes, J., Mackey, J., Spence, M. P., Koehler, M. T., & Slamon, D. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.581 · Cited by 12 · see citing works

The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans.

Denissen, J. F., Grabowski, B. A., Johnson, M. K., Boyd, S. A., Uchic, J. T., Stein, H. H., Cepa, S. P., & Hill, P. (1994) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08431-4 · Cited by 12 · see citing works

Disposition and metabolism of indeloxazine hydrochloride, a cerebral activator, in rats

Kamimura, H., Enjoji, Y., Sasaki, H., Kawai, R., Kaniwa, H., NIIGATA, K., & Kageyama, S. (1987) · Xenobiotica · doi:10.3109/00498258709043972 · Cited by 9 · see citing works

Metabolism of the aldose reductase inhibitor ALO1567 in man.

Park, Y., Hudson, J. L., Barker, R., York, B. M., & Brazzell, R. K. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb03885.x · Cited by 6 · see citing works

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246 · see citing works

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Ballard, P., Yates, J. W. T., Yang, Z., Kim, D.-W., Yang, J. C.-H., Cantarini, M., Pickup, K., Jordan, A., Hickey, M., Grist, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0399 · Cited by 718 · see citing works

Clinical pharmacokinetics of tyrosine kinase inhibitors

van Erp, N. P., Gelderblom, H., & Guchelaar, H.-J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.08.004 · Cited by 503 · see citing works

Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes

Li, J., Zhao, M., He, P., Hidalgo, M. M., & Baker, S. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0088 · Cited by 310 · see citing works

Morpholine as a privileged structure: A review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules

Kourounakis, A., Xanthopoulos, D., & Tzara, A. (2020) · Medicinal research reviews (Print) · doi:10.1002/med.21634 · Cited by 242 · see citing works

Toward precision medicine in glioblastoma: the promise and the challenges

Prados, M. D., Byron, S. A., Tran, N. L., Phillips, J. J., Molinaro, A. M., Ligon, K. L., Wen, P. Y., Kuhn, J. G., Mellinghoff, I. K., de Groot, J., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov031 · Cited by 228 · see citing works

METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS

Ling, J., Johnson, K. A., Miao, Z., Rakhit, A. K., Pantze, M. P., Hamilton, M., Lum, B. L., & Prakash, C. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007765 · Cited by 224 · see citing works

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

Gion, P. D., Kanefendt, F., Lindauer, A., Scheffler, M., Doroshyenko, O., Fuhr, U., Wolf, J., & Jaehde, U. (2011) · Clinical Pharmacokinetics · doi:10.2165/11593320-000000000-00000 · Cited by 224 · see citing works

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients

Li, J., Cusatis, G., Brahmer, J. R., Sparreboom, A., Robey, R. W., Bates, S. E., Hidalgo, M. M., & Baker, S. D. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.3.3763 · Cited by 191 · see citing works

The Biochemistry of Drug Metabolism – An Introduction

Testa, B., & Krämer, S. D. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790032 · Cited by 177 · see citing works

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions

Peters, S., Zimmermann, S., & Adjei, A. A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.010 · Cited by 155 · see citing works

Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain

Wu, C., Li, Y. L., Wang, Z. M., Li, Z., Zhang, T. X., & Wei, Z. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.03.011 · Cited by 149 · see citing works

Single-Dose Clinical Pharmacokinetic Studies of Gefitinib

Swaisland, H., Smith, R. P., Laight, A., Kerr, D. J., Ranson, M., Wilder‐Smith, C. H., & Duvauchelle, T. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544110-00004 · Cited by 142 · see citing works

Cytochrome P450-dependent metabolism of gefitinib

McKillop, D., McCormick, A., Millar, A., Miles, G. S., Phillips, P. J., & Hutchison, M. (2005) · Xenobiotica · doi:10.1080/00498250400026464 · Cited by 138 · see citing works

Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers

Stopfer, P., Marzin, K., Narjes, H., Gansser, D., Shahidi, M., Uttereuther-Fischer, M., & Ebner, T. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1803-9 · Cited by 137 · see citing works

Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population

Ma, S., Xu, Y., Deng, Q., & Yu, X. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.10.028 · Cited by 127 · see citing works

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI

Yi, H. G., Kim, H. J., Kim, Y. J., Han, S., Oh, D., Lee, S., Kim, D., Im, S., Kim, T., Kim, C. S., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.10.016 · Cited by 125 · see citing works

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor

McKillop, D., Partridge, E. A., Kemp, J. V., Spence, M. P., Kendrew, J., Barnett, S., Wood, P. G., Giles, P. B., Patterson, A. B., Bichat, F., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0329 · Cited by 125 · see citing works

FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management

Solassol, I., Pinguet, F., & Quantin, X. (2019) · Biomolecules · doi:10.3390/biom9110668 · Cited by 123 · see citing works

Metabolism considerations for kinase inhibitors in cancer treatment

Duckett, D. R., & Cameron, M. D. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.506873 · Cited by 111 · see citing works

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

Scheffler, M., Gion, P. D., Doroshyenko, O., Wolf, J., & Fuhr, U. (2011) · Clinical Pharmacokinetics · doi:10.2165/11587020-000000000-00000 · Cited by 110 · see citing works

Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall‐cell lung cancer

Lee, Y. J., Choi, H. J., Kim, S. I., Chang, J., Moon, J. W., Park, I. K., Kim, J.-H., & Cho, B. C. (2010) · Cancer · doi:10.1002/cncr.24877 · Cited by 106 · see citing works

CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors

Li, J., Karlsson, M. O., Brahmer, J. R., Spitz, A. N., Zhao, M., Hidalgo, M. M., & Baker, S. D. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj466 · Cited by 106 · see citing works

Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Gefitinib: Implications for Pulmonary and Hepatic Toxicities

Li, X., Kamenecka, T. M., & Cameron, M. D. (2009) · Chemical Research in Toxicology · doi:10.1021/tx900256y · Cited by 105 · see citing works

Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase

Wang, J.-Q., Gao, M., Miller, K. D., Sledge, G. W., & Zheng, Q. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.04.080 · Cited by 97 · see citing works

Biotransformation and bioactivation reactions of alicyclic amines in drug molecules

Bolleddula, J., DeMent, K., Driscoll, J. P., Worboys, P. D., Brassil, P. J., & Bourdet, D. L. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.924962 · Cited by 87 · see citing works

Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites

Lacy, S. A., Hsu, B. H., Miles, D., Aftab, D. T., Wang, R., & Nguyen, L. T. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.063610 · Cited by 80 · see citing works

Pharmacokinetics of gefitinib in humans: The influence of gastrointestinal factors

Bergman, E., Forsell, P., Persson, E. M., Knutson, L., Dickinson, P. A., Smith, R. P., Swaisland, H., Farmer, M. R., Cantarini, M., & Lennernäs, H. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.04.002 · Cited by 69 · see citing works

Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia

Dennis, M., Davies, M., Oliver, S. D., D'Souza, R. A., Pike, L., & Stockman, P. K. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1939-2 · Cited by 68 · see citing works

Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non–Small-Cell Lung Cancer

Kobayashi, H., Sato, K., Niioka, T., Miura, H., Ito, H., & Miura, M. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.12.004 · Cited by 61 · see citing works

In vitrometabolism of gefitinib in human liver microsomes

McKillop, D., McCormick, A., Miles, G. S., Phillips, P. J., Pickup, K., Bushby, N., & Hutchison, M. (2004) · Xenobiotica · doi:10.1080/02772240400015222 · Cited by 61 · see citing works

Recent advances in metabolism and toxicity of tyrosine kinase inhibitors

Zhao, Q., Wu, Z. E., Li, B., & Li, F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108256 · Cited by 60 · see citing works

Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?

Rukazenkov, Y., Speake, G., Marshall, G. B., Anderton, J., Davies, B. R., Wilkinson, R. W., Hickinson, D. M., & Swaisland, A. J. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833034e1 · Cited by 59 · see citing works

Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer

Xu, Z., & Li, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s194870 · Cited by 58 · see citing works

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib

Araki, T., Yashima, H., Shimizu, K., Aomori, T., Hashita, T., Kaira, K., Nakamura, T., & Yamamoto, K. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7340 · Cited by 56 · see citing works

A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans

Bi, Y., Deng, J., Murry, D. J., & An, G. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9836-3 · Cited by 52 · see citing works

Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism

Liu, X., Lu, Y., Guan, X., Dong, B., Chavan, H. D., Wang, J., Zhang, Y., Krishnamurthy, P. C., & Li, F. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.010 · Cited by 51 · see citing works

Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis

Chen, Y., Wang, M., Zhong, W., & Zhao, J. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.013 · Cited by 48 · see citing works

Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog

McKillop, D., Partridge, E. A., Hutchison, M., Rhead, S., Parry, A. C., Bardsley, J., Woodman, H. M., & Swaisland, H. (2004) · Xenobiotica · doi:10.1080/00498250400009189 · Cited by 46 · see citing works

Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines

Alfieri, R. R., Galetti, M., Tramonti, S., Andreoli, R., Mozzoni, P., Cavazzoni, A., Bonelli, M. A., Fumarola, C., Monica, S. L., Galvani, E., et al. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-143 · Cited by 46 · see citing works

Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes

Han, S., Zhao, H., Zhou, N., Zhou, F., & Li, P. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.10.021 · Cited by 44 · see citing works

Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens

Pratz, K. W., & Levis, M. J. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190801895352 · Cited by 44 · see citing works

A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism

Barzi, M., Pankowicz, F. P., Zorman, B., Liu, X., Legras, X. D., Yang, D., Borowiak, M., Bissig-Choisat, B., Sumazin, P., Li, F., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00049-x · Cited by 43 · see citing works

Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity

Paludetto, M., Puisset, F., Chatelut, É., & Arellano, C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21577 · Cited by 43 · see citing works

Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents

Min, J., Guo, K., Suryadevara, P. K., Zhu, F., Holbrook, G., Chen, Y., Féau, C., Young, B. M., Lemoff, A. S., Connelly, M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01092 · Cited by 42 · see citing works

Does Sarcopenia Affect Outcome in Patients with Non-Small-Cell Lung Cancer Harboring EGFR Mutations?

Rossi, S., Noia, V. D., Tonetti, L., Strippoli, A., Basso, M., Schinzari, G., Cassano, A., Leone, A., Barone, C., & D’Argento, E. (2018) · Future Oncology · doi:10.2217/fon-2017-0499 · Cited by 40 · see citing works

Physicochemical Properties of Epidermal Growth Factor Receptor Inhibitors and Development of a Nanoliposomal Formulation of Gefitinib

Trummer, B. J., Iyer, V., Balu‐Iyer, S. V., O'Connor, R. A., & Straubinger, R. M. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23180 · Cited by 39 · see citing works

Gefitinib–phenytoin interaction is not correlated with the14C‐erythromycin breath test in healthy male volunteers

Chhun, S., Verstuyft, C., Rizzo‐Padoin, N., Simoneau, G., Becquemont, L., Idy-Peretti, I., Swaisland, A. J., Wortelboer, R., Bergmann, J., & Mouly, S. J. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03438.x · Cited by 39 · see citing works

Successful Treatment of Carcinomatous Meningitis with Gefitinib in a Patient with Lung Adenocarcinoma Harboring a Mutated EGF Receptor Gene

Fukuhara, T., Saijo, Y., Sakakibara, T., Inoue, A., Morikawa, N., Kanamori, M., Nakashima, I., & Nukiwa, T. (2008) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.214.359 · Cited by 37 · see citing works

The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib

Horák, J., White, J., Harris, A. L., Verrill, M. W., Carmichael, J., Holt, A., Cantarini, M., Macpherson, M. P., Swaisland, A. J., Swaisland, H., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1611-2 · Cited by 35 · see citing works

The use of the dog electroencephalogram (EEG) in safety pharmacology to evaluate proconvulsant risk

Dürmüller, N., Guillaume, P., Lacroix, P., Porsolt, R. D., & Moser, P. C. (2007) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2007.03.006 · Cited by 35 · see citing works

Expression of epidermal growth factor receptor in canine osteosarcoma: Association with clinicopathological parameters and prognosis

Selvarajah, G. T., Verheije, M. H., Kik, M. J. L., Slob, A., Rottier, P. J. M., Mol, J. A., & Kirpensteijn, J. (2012) · The Veterinary Journal · doi:10.1016/j.tvjl.2012.02.009 · Cited by 35 · see citing works

Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines

Galetti, M., Alfieri, R. R., Cavazzoni, A., Monica, S. L., Bonelli, M. A., Fumarola, C., Mozzoni, P., Palma, G. D., Andreoli, R., Mutti, A., et al. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.03.033 · Cited by 34 · see citing works

Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib

Kobayashi, H., Sato, K., Niioka, T., Takeda, M., Okuda, Y., Asano, M., Ito, H., & Miura, M. (2016) · Medical Oncology · doi:10.1007/s12032-016-0773-5 · Cited by 32 · see citing works

Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro

Festuccia, C., Gravina, G. L., Biordi, L. A., D’Ascenzo, S., Dolo, V., Ficorella, C., Ricevuto, E., & Tombolini, V. (2009) · The Prostate · doi:10.1002/pros.20995 · Cited by 31 · see citing works

Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases

Luo, S., Chen, L., Chen, X., & Xie, X. (2015) · Oncotarget · doi:10.18632/oncotarget.4264 · Cited by 30 · see citing works

Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review

Nijenhuis, C. M., Schellens, J. H. M., & Beijnen, J. H. (2016) · Drug Metabolism Reviews · doi:10.1080/03602532.2016.1181081 · Cited by 30 · see citing works

Safe handling of oral antineoplastic medications: Focus on targeted therapeutics in the home setting

Cass, Y., Connor, T. H., & Tabachnik, A. (2016) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155216637217 · Cited by 29 · see citing works

Decreased Biosynthesis of Lung Surfactant Constituent Phosphatidylcholine Due to Inhibition of Choline Transporter by Gefitinib in Lung Alveolar Cells

Ishiguro, N., Oyabu, M., Sato, T., Maeda, T., Minami, H., & Tamai, I. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9362-9 · Cited by 28 · see citing works

Metabolite characterization of a novel anti‐cancer agent, icotinib, in humans through liquid chromatography/quadrupole time‐of‐flight tandem mass spectrometry

Liu, D., Jiang, J., Zhang, L., Tan, F., Wang, Y., & Hu, P. (2011) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.5061 · Cited by 26 · see citing works

Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition

McKillop, D., Guy, S. P., Spence, M. P., Kendrew, J., Kemp, J. V., Bushby, N., Wood, P. G., Barnett, S., & Hutchison, M. (2006) · Xenobiotica · doi:10.1080/00498250500523253 · Cited by 25 · see citing works

Gefitinib for the treatment of non-small-cell lung cancer

Campbell, L., Blackhall, F. H., & Thatcher, N. J. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.481283 · Cited by 25 · see citing works

In vitrometabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes

Nakagawa, T., Fowler, S. M., Takanashi, K., Youdim, K. A., Yamauchi, T., Kawashima, K., Sato-Nakai, M., Yu, L. J., & Ishigai, M. (2017) · Xenobiotica · doi:10.1080/00498254.2017.1344910 · Cited by 22 · see citing works

Metabolites of alectinib in human: their identification and pharmacological activity

Sato-Nakai, M., Kawashima, K., Nakagawa, T., Tachibana, Y., Yoshida, M., Takanashi, K., Morcos, P. N., Binder, M., Moore, D. J., & Yu, L. J. (2017) · Heliyon · doi:10.1016/j.heliyon.2017.e00354 · Cited by 22 · see citing works

Gefitinib in the treatment of advanced non-small-cell lung cancer

Reck, M. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.1 · Cited by 22 · see citing works

Intratumoral Modeling of Gefitinib Pharmacokinetics and Pharmacodynamics in an Orthotopic Mouse Model of Glioblastoma

Sharma, J., Lv, H., & Gallo, J. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0690 · Cited by 21 · see citing works

Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

Couñago, F., Pérez, A. R., Calvo, P., Luna, J., Monroy, J. L., Taboada, B., Díaz, V. D., & de Dios, N. R. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1512-2 · Cited by 21 · see citing works

Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment

Kim, H.-R., Lee, J. C., Kim, Y., Kim, K. S., Oh, I., Lee, S. Y., Jang, T. W., Lee, M. K., Shin, K. C., Lee, G. H., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.008 · Cited by 21 · see citing works

Comparison of Gefitinib Versus VMP in the Combination with Radiotherapy for Multiple Brain Metastases from Non-small Cell Lung Cancer

Wang, F., Ning, F., Liu, C., Hao, Y., Li, L., Yu, Z., Chen, S., & Li, B. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0286-9 · Cited by 20 · see citing works

Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3

Sato, T., Ito, H., Hirata, A., Abe, T., Mano, N., & Yamaguchi, H. (2016) · Xenobiotica · doi:10.1080/00498254.2016.1275880 · Cited by 19 · see citing works

Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer

Kawata, T., Higashimori, M., Itoh, Y., Tomkinson, H. K., Johnson, M. G., Tang, W., Nyberg, F., Jiang, H., & Tanigawara, Y. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03788-4 · Cited by 18 · see citing works

Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer

Yuan, Y., Li, X., Chen, J., Dong, Weng, S., & Huang, J. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s34124 · Cited by 17 · see citing works

Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu

Piechocki, M. P., Dibbley, S. K., Lonardo, F., & Yoo, G. H. (2007) · International Journal of Cancer · doi:10.1002/ijc.23231 · Cited by 17 · see citing works

Tyrosine Kinase Inhibitors

Cismowski, M. J. (2007) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.61004-9 · Cited by 16 · see citing works

Molecular pharmacokinetic determinants of anticancer kinase inhibitors in humans

Scholler, J., & Levêque, D. (2011) · Oncology Reviews · doi:10.1007/s12156-011-0072-5 · Cited by 16 · see citing works

Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan

Luong, T.-L. T., McAnulty, M. J., Evers, D. L., Reinhardt, B. J., & Weina, P. J. (2021) · Current Research in Toxicology · doi:10.1016/j.crtox.2021.05.006 · Cited by 15 · see citing works

Tentative identification of gefitinib metabolites in non-small-cell lung cancer patient plasma using ultra-performance liquid chromatography coupled with triple quadrupole time-of-flight mass spectrometry

Wang, C., Zhang, J., Zhou, S., Yu, L., Han, F., Ling, R., & Ling, J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236523 · Cited by 15 · see citing works

Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients

Guan, Y., Li, M., He, Q. W., Li, M., & Luo, F. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s80635 · Cited by 15 · see citing works

Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan

Lin, C., Hsu, K.-H., Chang, S., Tsou, H., Sheehan, J. P., Sheu, M., & Pan, H.-C. (2015) · Radiation Oncology · doi:10.1186/s13014-015-0431-7 · Cited by 15 · see citing works

Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [14C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers

Gerisch, M., Schwarz, T., Lang, D. H., Rohde, G., Reif, S., Genvresse, I., Reschke, S., van der Mey, D., & Granvil, C. P. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3383-9 · Cited by 15 · see citing works

Computational Prediction of the Site(s) of Metabolism and Binding Modes of Protein Kinase Inhibitors Metabolized by CYP3A4

Nair, P. C., McKinnon, R. A., & Miners, J. O. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.085167 · Cited by 15 · see citing works

The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor

Högnäsbacka, A., Poot, A. J., Vugts, D. J., van Dongen, G. A. M. S., & Windhorst, A. D. (2022) · Pharmaceuticals · doi:10.3390/ph15040450 · Cited by 14 · see citing works

The tyrosine kinase inhibitor PD153035: implication of labeling position on radiometabolites formed in vitro

Samén, E., Thorell, J.-O., Fredriksson, A., & Stone‐Elander, S. (2006) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2006.09.008 · Cited by 14 · see citing works

Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer

Guan, S., Chen, X., Xin, S., Liu, S., Yang, Y., Fang, W., Huang, Y., Zhao, H., Zhu, X., Zhuang, W., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100951 · Cited by 13 · see citing works

Rapid determination of the pharmacokinetics and metabolic fate of gefitinib in the mouse using a combination of UPLC/MS/MS, UPLC/QToF/MS, and ion mobility (IM)-enabled UPLC/QToF/MS

Molloy, B. J., King, A. M., Mullin, L. G., Gethings, L. A., Riley, R. J., Plumb, R. S., & Wilson, I. D. (2020) · Xenobiotica · doi:10.1080/00498254.2020.1859643 · Cited by 13 · see citing works

High Throughput UHPLC-MS-Based Lipidomics Using Vacuum Jacketed Columns

Plumb, R. S., Isaac, G., Rainville, P. D., Hill, J. F., Gethings, L. A., Johnson, K. A., Lauterbach, J. D., & Wilson, I. D. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00836 · Cited by 13 · see citing works

Prognostic value of sarcopenia in patients with lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors

Lyu, J., Yang, N., Xiao, L., Nie, X., Xiong, J., Liu, Y., Zhang, M., Zhang, H., Tang, C., Pan, S., et al. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1113875 · Cited by 12 · see citing works

HB-EGF activates EGFR to induce reactive neural stem cells in the mouse hippocampus after seizures

Pastor-Alonso, O., Durá, I., Bernardo-Castro, S., Varea, E., Muro‐García, T., Martín‐Suárez, S., Encinas, J. M., & Pineda, J. R. (2024) · Life Science Alliance · doi:10.26508/lsa.202201840 · Cited by 12 · see citing works

Marsdenia tenacissima extract promotes gefitinib accumulation in tumor tissues of lung cancer xenograft mice via inhibiting ABCG2 activity

Zhao, C., Hao, H., Zhao, H., Ren, W., Jiao, Y., An, G., Sun, H., Han, S., & Li, P. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112770 · Cited by 12 · see citing works

The Pharmacometabodynamics of Gefitinib after Intravenous Administration to Mice: A Preliminary UPLC–IM–MS Study

Molloy, B. J., Mullin, L. G., King, A. M., Gethings, L. A., Plumb, R. S., & Wilson, I. D. (2021) · Metabolites · doi:10.3390/metabo11060379 · Cited by 11 · see citing works

Method validation and characterization of stress degradation products of gefitinib through UPLC-UV/PDA and LC–MS/TOF studies

Patra, S. R., Bali, A., Saha, M., Singh, J., & Shekhar, S. (2023) · International Journal of Mass Spectrometry · doi:10.1016/j.ijms.2023.117070 · Cited by 11 · see citing works

Hybrid organic/inorganic hybrid surface technology for increasing the performance of LC/MS(MS)-based drug metabolite identification studies: Application to gefitinib and metabolites in mouse plasma and urine

Plumb, R. S., Gethings, L. A., King, A. M., Mullin, L. G., Maker, G. L., Trengove, R. D., & Wilson, I. D. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114076 · Cited by 11 · see citing works

Improving LC/MS/MS-based bioanalytical method performance and sensitivity via a hybrid surface barrier to mitigate analyte – Metal surface interactions

Tanna, N., Mullin, L. G., Rainville, P. D., Wilson, I. D., & Plumb, R. S. (2021) · Journal of Chromatography B · doi:10.1016/j.jchromb.2021.122825 · Cited by 11 · see citing works

Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine

Luong, T.-L. T., Powers, C. N., Reinhardt, B. J., & Weina, P. J. (2022) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2022.100112 · Cited by 10 · see citing works

FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy

Guan, S., Chen, X., Chen, Y., Wan, G., Su, Q., Liang, H., Yang, Y., Fang, W., Huang, Y., Zhao, H., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.006 · Cited by 10 · see citing works

Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation

Igawa, S., Kasajima, M., Ishihara, M., Kimura, M., Hiyoshi, Y., Niwa, H., Kusuhara, S., Harada, S., Asakuma, M., Otani, S., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2570-1 · Cited by 10 · see citing works

Derivative Spectrophotometric Methods for Determination of Gefitinib in Bulk and in Formulation

Patra, S. R., Bali, A., & Saha, M. (2021) · Journal of Applied Spectroscopy · doi:10.1007/s10812-021-01284-3 · Cited by 8 · see citing works

Single-cell mass spectrometry studies of drug metabolism heterogeneity and primary resistance to gefitinib in non-small cell lung cancer cells

Zhu, G., Zhao, Y., Zhang, W., Wu, Y., Liu, Y., Guo, G., Wang, X., & Liu, Z. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108466 · Cited by 8 · see citing works

Comprehensive identification, fragmentation pattern, and metabolic pathways of gefitinib metabolites via UHPLC-Q-TOF-MS/MS: in vivo study of rat plasma, urine, bile, and faeces

Gao, X., Zhang, Y., Feng, T., Cao, L., Wu, W., & Qin, K. (2020) · Xenobiotica · doi:10.1080/00498254.2020.1859642 · Cited by 8 · see citing works

Detection of pharmacolipidodynamic effects following the intravenous and oral administration of gefitinib to C57Bl/6JRj mice by rapid UHPLC-MS analysis of plasma

Plumb, R. S., Gethings, L. A., Isaac, G., Munjoma, N. C., & Wilson, I. D. (2024) · Scientific Reports · doi:10.1038/s41598-024-66764-w · Cited by 7 · see citing works

Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog

McKillop, D., Partridge, E. A., Hutchison, M., Rhead, S., Parry, A. C., Bardsley, J., Woodman, H. M., & Swaisland, H. (2004) · Xenobiotica · doi:10.1080/00498250400009189 · Cited by 46 · see citing works

In vitrometabolism of gefitinib in human liver microsomes

McKillop, D., McCormick, A., Miles, G. S., Phillips, P. J., Pickup, K., Bushby, N., & Hutchison, M. (2004) · Xenobiotica · doi:10.1080/02772240400015222 · Cited by 61 · see citing works

Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor

Scheers, E. M., Borgmans, C., Keung, C., Bohets, H., Wynant, I., Poggesi, I., Cuyckens, F., Leclercq, L., & Mamidi, R. N. V. S. (2020) · Xenobiotica · doi:10.1080/00498254.2020.1821123 · Cited by 12 · see citing works

Comprehensive identification, fragmentation pattern, and metabolic pathways of gefitinib metabolites via UHPLC-Q-TOF-MS/MS: in vivo study of rat plasma, urine, bile, and faeces

Gao, X., Zhang, Y., Feng, T., Cao, L., Wu, W., & Qin, K. (2020) · Xenobiotica · doi:10.1080/00498254.2020.1859642 · Cited by 8 · see citing works

Cytochrome P450-dependent metabolism of gefitinib

McKillop, D., McCormick, A., Millar, A., Miles, G. S., Phillips, P. J., & Hutchison, M. (2005) · Xenobiotica · doi:10.1080/00498250400026464 · Cited by 138 · see citing works